

Current Recruiting Interventional Studies for Sudden Sensorineural Hearing Loss

Title of Study	Link	Brief Summary	Sponsor
North America			
Oral Statins and Protection From Hearing Loss	https://clinicaltrials.gov/study/NCT04826237	A small clinical trial for idiopathic sudden sensorineural hearing loss (ISSNHL). Will the addition of an oral statin to the standard treatment (oral methylprednesolone and the salvage therapy of intratympanic dexamethasone) improve the treatment outcome for patients with ISSNHL? This study will compare the two treatments and quantitatively evaluate hearing and speech discrimination and have the patients subjectively evaluate tinnitus.	Northwestern University
Europe			
Efficacy and Safety of AC102 Compared to Steroids in Adults With Idiopathic Sudden Sensorineural Hearing Loss (ISSNHL)	https://clinicaltrials.gov/study/NCT05776459	The purpose of this Phase 2 clinical trial is to evaluate the safety, tolerability and efficacy of AC102 administered as single intratympanic injection compared to oral steroid treatment in patients with Idiopathic Sudden Sensorineural Hearing Loss (ISSNHL).	AudioCure Pharma GmbH
Asia			
The Role of Migraine Prophylaxis Agent Topiramate in Treating Patients With Sudden Sensorineural Hearing Loss	https://clinicaltrials.gov/study/NCT05403229	Migraine and sudden sensorineural hearing loss(SSNHL) are two related disorders. A systemic steroid is usually used to treat SSNHL but the role of migraine prophylaxis medication remained unknown. Mehdi Abouzari et al. found a better improvement when combining topiramate and nortriptyline with steroids in a retrospective study. However, a prospective study with randomization is needed to elucidate the efficacy of these agents. This is a clinical study using medication approved and currently prescribed in the clinic. The included patients were those who came to the clinic and were diagnosed with SSNHL within 14 days of onset. Those patients were asked whether they agreed to participate in this clinical trial. Patients who were diagnosed with SSNHL but were later found to be other diseases such as Meniere's disease and cerebellopontine angle will be excluded from this study.	Chang Gung Memorial Hospital

		<p>The involved patients were randomized divided into two groups. Both groups received systemic steroids with/without intratympanic steroids. The experimental group receives additional oral topiramate for 6 weeks.</p> <p>Follow-up time is at least 3 months.</p> <p>This study is multi-center. Location of the study is performed at Chang gung memorial hospital Linkou branch, Taipei branch, Taoyuan branch, and New Taipei Municipal Tucheng Hospital.</p>	
<p>A Phase 1b/2a, Study Evaluating the Safety, PK/PD and Efficacy of NS101 in Healthy Volunteers and SSNHL Patients</p>	<p>https://clinicaltrials.gov/study/NCT06249919</p>	<p>The goal of this 2 step-up, exploratory study is to test safety, tolerability and PK/PD profiles in healthy volunteers and safety, tolerability and efficacy in sudden sensorineural hearing loss patients as an early salvage therapy.</p> <p>The main questions it aims to answer are:</p> <ol style="list-style-type: none"> 1. whether is it safe and tolerable when healthy volunteers and sudden sensorineural hearing loss patients take multiple doses of NS101 against FAM19A5 2. whether is it effective in reversing hearing capability in sudden sensorineural hearing loss patients who fails to show sufficient recovery despite of oral standard steroid therapy. <p>Patients and healthy volunteers will be given NS101 15mg/kg or 30mg/kg systemically less than 3 months per protocol.</p> <p>This is placebo controlled, double blinded study, which means there will be a group who receives placebo (i.e. fake drug) for study purpose.</p>	<p>Neuracle Science Co., LTD.</p>